

The invisible and unknown pathologist!

Prof. dr. Jo Van Dorpe, dienst Pathologische Anatomie



Inhoud

- ▶ Misverstanden over pathologie
 - ▶ Beweringen over pathologie die waar zijn
 - ▶ ‘Moderne’ pathologie
 - ▶ De toekomst
 - ▶ Conclusie
- 

Misverstanden over pathologie (1)


- ▶ ‘Voor pathologie heb je geen *social skills* nodig’
- ▶ ‘lets voor *nerds*’
- ▶ ‘lets voor autisten’
- ▶ ‘De patholoog zit in een kelder’



Misverstanden over pathologie (2)

- ▶ 'Weinig werken en veel koffie drinken'

Aantal blokken en aantal laboranten per jaar



Misverstanden over pathologie (3)

- ▶ 'De patholoog is geen echte arts'
- ▶ 'De patholoog ziet geen patiënten'



Misverstanden over pathologie (4)


- ▶ 'Pathologie is een laboratoriumspecialisme'


= WAAR en NIET-waar

Veel manuele stappen!
Erg arbeidsintensief!











16B21551



Pathologische anatomie = klinisch
specialisme!



Plaveiselcelcarcinoma





Hodgkin-lymfoma

Autopsies



Beweringen over pathologie die waar zijn (1)

- ▶ ‘Een patholoog moet veel kennen en kunnen’



Beweringen over pathologie die waar zijn (2)

- ▶ 'Pathologen doen hun vak met veel passie'

Beweringen over pathologie die waar zijn (3)



- ▶ 'Geen oncologie zonder pathologie'

Beweringen over pathologie die waar zijn (4)



- ▶ 'Pathologie is *service-verlenend*'

'Moderne' pathologie


- ▶ Immunohistochemie
- ▶ Moleculaire pathologie



?



1) Immunohistochemie = eiwitniveau






**Borstcarcinoma met over-
expressie van HER2**

Immuunhistochemie


- ▶ Typering van tumoren
 - ▶ Prognose
 - ▶ Predictief
 - ▶ Aantonen mutaties
 - ▶ Identificatie van micro-organismen
- 



CD45+, CD20+




B-cel lymfoom



S100+, SOX10+




melanoma



CD99+, NKX2.2+



.....



CD99+, NKX2.2 negatief




.....


2) Moleculaire pathologie = op DNA- en RNA-niveau


- ▶ FISH-analyse
- ▶ *Next generation sequencing:*
 - Op DNA-niveau
 - Op gen-niveau: mutatie-analyse
 - Op chromosomaal niveau: *copy number variant sequencing*
 - Op RNA-niveau: gen-fusie-detectie

FISH-analyse (1)




Normale cel






Borstcarcinooma




FISH-analyse (2)




EWS 22




FLI1 11



EWS-FLI1 t(11;22)




FLI1-EWS t(11;22)



CD45+, CD20+




B-cel lyfmoom



S100+, SOX10+



melanoma




CD99+, NKX2.2+

FISH:
EWSR1-
herschikking



Ewing-
sarcoma




CD99+, NKX2.2 negatief

FISH:
EWSR1-
herschikking



?




Moleculaire diagnostiek Gent (MDG)




RNA-niveau: gen-fusie-detectie

- ▶ *ALK, BCOR, BRAF, CAMTA1, CCNB3, CIC, CSF1, EPC1, EWSR1, FGFR1, FGFR2, FGFR3, FOSB, FOXO1, FUS, GLI1, HMGA2, JAZF1, MEAF6, MKL2, NCOA2, NR4A3, NTRK1, NTRK2, NTRK3, NUTM1, PAX3, PDGFB, PHF1, PLAG1, RET, ROS1, SS18, STAT6, TAF15, TCF12, TFE3, TFG, USP6, YWHAE*

— Ewing's Sarcoma
 — Alveolar Rhabdomyosarcoma
 — Synovial Sarcoma
 — Myxoid Liposarcoma
 — Other subtypes






CD45+, CD20+




B-cel lymfoom



S100+, SOX10+



melanoma




CD99+, NKX2.2

FISH:
EWSR1-
herschikking



Ewing-
sarcoma



CD99+, NKX2.2 negatief

EWSR1-
SSX2-
herschikking



Ewing-like sarcoma met EWSR1-SSX2
fusie!!!

Received: 24 June 2021 | Revised: 31 August 2021 | Accepted: 14 September 2021

DOI: 10.1002/gcc.22999

BRIEF REPORT

WILEY


Undifferentiated sarcoma of bone with a round to epithelioid cell phenotype harboring a novel *EWSR1-SSX2* fusion identified by RNA-based next-generation sequencing

Fleur Cordier¹  | Joni Van der Meulen^{2,3} | Bram Van Gaever¹ | Lore Lapeire^{3,4} |
Gwen Sys^{3,5} | Jo Van Dorpe^{1,3}  | David Creytens^{1,3} 

Genes Chromosomes and Cancer, 2022 Jan; 61(1): 44-49.

De toekomst

- ▶ Moleculaire pathologie zal nog aan belang toenemen
- ▶ **Liquid biopsies**
- ▶ Epigenetica: **methylatie-profiling**



- ▶ Sub-specialistie: **dedicated specialist** in orgaan-specifieke tumordiagnostiek
- ▶ Digitalisatie en **artificiële intelligentie**



Shallow-depth sequencing of cell-free DNA for Hodgkin and diffuse large B-cell lymphoma (differential) diagnosis: a standardized approach with underappreciated potential

Lennart Raman,^{1,2*} Malaika Van der Linden,^{1,2,*} Ciel De Vriendt,^{3,*} Bliede Van den Broeck,⁴ Kristoff Muylle,⁵ Dries Deeren,⁶ Francesca Dedeurwaerdere,⁷ Sofie Verbeke,² Amélie Dendooven,^{2,8} Katrien De Grove,³ Saskia Baert,³ Kathleen Claes,² Björn Menten,² Fritz Offner^{3*} and Jo Van Dorpe^{1*}

¹Department of Pathology, Ghent University, Ghent University Hospital, Ghent; ²Center for Medical Genetics, Department of Biomolecular Medicine, Ghent University, Ghent University Hospital, Ghent; ³Department of Clinical Hematology, Ghent University, Ghent University Hospital, Ghent; ⁴Department of Nuclear Medicine, Ghent University, Ghent University Hospital, Ghent; ⁵Department of Nuclear Medicine, AZ Delta, Roeselare; ⁶Department of Hematology, AZ Delta, Roeselare; ⁷Department of Pathology, AZ Delta, Roeselare and ⁸Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium

*LR, MVDL and CDV contributed equally as co-first authors.

*JVD and FO contributed equally as co-senior authors.

Haematologica 2022
Volume 107(1):211-220

ABSTRACT

Shallow-depth sequencing of cell-free DNA, an inexpensive and standardized approach to obtain molecular information on tumors non-invasively, has been insufficiently explored for the diagnosis of lymphoma and disease follow-up. This study collected 318 samples, including longitudinal liquid and paired solid biopsies, from a prospectively-recruited cohort of 38 Hodgkin lymphoma (HL) and 85 aggressive B-cell non-HL patients, represented by 81 diffuse large B-cell lymphoma (DLBCL) cases. Following sequencing, copy number alterations and viral read fractions were derived and analyzed. At diagnosis, liquid biopsies showed detectable copy number alterations in 84.2% of HL patients (88.6% for classical HL) and 74.1% of DLBCL patients. Of the DLBCL patients, copy number profiles between liquid-solid pairs were highly concordant ($r=0.815\pm 0.043$); and, compared to tissue, HL liquid biopsies had abnormalities with higher amplitudes ($P=0.010$). This implies that tumor DNA is more abundant in plasma. Additionally, 39.5% of HL and 13.6% of DLBCL cases had a significantly elevated number of plasma Epstein-Barr virus DNA fragments, achieving a sensitivity of 100% compared to the current standard. A longitudinal analysis determined that, when detectable, copy number patterns were similar across (re)staging moments in refractory or relapsed patients. Further, the overall profile anomaly correlated highly with the total metabolic tumor volume ($P<0.001$). To conclude, as a proof of principle, we demonstrate that liquid biopsy-derived copy numbers can aid diagnosis: e.g., by differentiating HL from DLBCL, random forest modeling is represented by an area under the receiver operating characteristic curve of 0.967. This application is potentially useful when tissue is difficult to obtain or when biop-

Correspondence:

JO VAN DORPE
Jo.VanDorpe@uzgent.be

Received: August 3, 2020.

Accepted: November 25, 2020.

Pre-published: December 10, 2020.

<https://doi.org/10.3324/haematol.2020.268813>

©2022 Ferrata Storti Foundation

Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of

Open Access



Shallow whole-genome sequencing of plasma cell-free DNA accurately differentiates small from non-small cell lung carcinoma

Lennart Raman^{1,2*}, Malaika Van der Linden^{1†}, Kim Van der Eecken^{1†}, Karim Vermaelen³, Ingel Demedts⁴, Veerle Surmont³, Ulrike Himpe⁴, Francesca Dedeurwaerdere⁵, Liesbeth Ferdinande¹, Yolande Lievens⁶, Kathleen Claes², Björn Menten^{2†} and Jo Van Dorpe^{1†*}

Abstract

Background: Accurate lung cancer classification is crucial to guide therapeutic decisions. However, histological subtyping by pathologists requires tumor tissue—a necessity that is often intrinsically associated with procedural difficulties. The analysis of circulating tumor DNA present in minimal-invasive blood samples, referred to as liquid biopsies, could therefore emerge as an attractive alternative.

Methods: Concerning adenocarcinoma, squamous cell carcinoma, and small cell carcinoma, our proof of concept study investigates the potential of liquid biopsy-derived copy number alterations, derived from single-end shallow whole-genome sequencing (coverage 0.1–0.5x), across 51 advanced stage lung cancer patients.

Results: Genomic abnormality testing reveals anomalies in 86.3% of the liquid biopsies (16/20 for adenocarcinoma, 13/16 for squamous cell, and 15/15 for small cell carcinoma). We demonstrate that copy number profiles from formalin-fixed paraffin-embedded tumor biopsies are well represented by their liquid equivalent. This is especially valid within the small cell carcinoma group, where paired profiles have an average Pearson correlation of 0.86 (95% CI 0.79–0.93). A predictive model trained with public data, derived from 843 tissue biopsies, shows that liquid biopsies exhibit multiple deviations that reflect histological classification. Most notably, distinguishing small from non-small cell lung cancer is characterized by an area under the curve of 0.98 during receiver operating characteristic analysis. Additionally, we investigated how deeper paired-end sequencing, which will eventually become feasible for routine diagnosis, empowers tumor read enrichment by insert size filtering: for all of the 29 resequenced liquid biopsies, the tumor fraction could be increased in silico, thereby “rescuing” three out of five cases with previously undetectable alterations.

(Continued on next page)

* Correspondence: Jo.VanDorpe@uzgent.be

†Lennart Raman, Malaika Van der Linden, and Kim Van der Eecken contributed equally to this work.


Björn Menten and Jo Van Dorpe are considered shared last authors.

¹Department of Pathology, Ghent University Hospital, Ghent University, Coupurelaan 10, 9000 Ghent, Belgium


Conclusie

- ▶ Ruim, maar dan ook ruim het **boeiendste** van alle specialismen
 - ▶ Echt iets voor **detectieven**
 - ▶ **Klinische vaardigheid** gelinkt aan **theoretische kennis**
 - ▶ Stellen van diagnose is **multidisciplinair**
- 

Histology




Gross examination



Clinical history
Radiology




Immunohistochemistry



MOC

Molecular Pathology (NGS)00



Bedankt voor de aandacht!

